Our comprehensive search did not reveal any systematic reviews that quantitatively compared the efficacy of PI3K/AKT/mTOR inhibitors specifically in RA-FLSs, whereas isolated in vivo investigations provide only indirect support for the promise of combinatorial inhibition [11,12]. This evidence concerns the gene MTOR and rheumatoid arthritis.